TRELLUS HEALTH PLC (TRLS) — Interim Results 30th June 2024

Investor webinar replay

Replay transcript excerpt

Good morning, Dick. Thank you very much. I'm here with our CFO, Joy Besacher, and we're delighted to be presenting our interim results for the period ending June 30. So here is our disclaimer slide. So let's dig in. As a reminder, it's always good to set the tone as to what Trellis is and do a company overview. So Trellis Health delivers a validated, personalized solution for managing chronic conditions called TRELLUS Elevate that's been proven to enhance outcomes, improve adherence to medications and treatment plans, and lowers the costs associated with complex chronic condition management. Leveraging proprietary resilience building approach, we provide significant value to both health plans and the pharmaceutical sector. So in our interim 2024 highlights, I would like to share with you that we signed and launched our first commercial scale pilot, a large US health plan. We signed two licensing agreements with pharma for proprietary assessments and content. We announced our new board chair with extensive US health experience, Mr. Kevin Murphy. We received and maintain our SOC two Type two certification, meeting industry standards for system security and reliability. We have sustained operational scalability while extending our cash runway into late Q3 twenty twenty five, and we are advancing discussions with potential partners across all our verticals. Post period highlights include extended enrollment for our large health plan beyond the initial six month enrollment period, which we had described previously. Brian Griffin was appointed to the Board of Directors and also brings U. S. Healthcare and pharmaceutical sector expertise. So a high level summary of our large health plan program. It was launched in March 2024 and as a reminder it was covering two states, bot...